Clare Arnott's Publications

About Clare Arnott's Publications

Global Director, Cardiovascular Program
  • Co-Director, Global Chronic & Complex Diseases
  • BMed Sci,
  • MBBS (Hons),
  • PhD,
  • FRACP,
  • FESC,
  • CF

  • Protocol for a novel sodium and blood pressure reduction intervention targeting online grocery shoppers with hypertension - the SaltSwitch Online Grocery Shopping randomized trial

    American Heart Journal Date published:

  • Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk

    Heart Failure Clinics Date published:

  • Sex disaggregated analysis of risk factors for adverse outcomes in hypertrophic cardiomyopathy

    European Heart Journal Date published:

  • Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure

    Cardiovascular Diabetology Date published:

  • Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS

    Diabetes Care Date published:

  • Multidisciplinary perspectives on the role of primary care in managing chronic breathlessness

    01.03 - General practice and primary care Date published:

  • Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program

    Diabetes, Obesity and Metabolism Date published:

  • Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

    Journal of the American Heart Association Date published:

  • Radial First in Primary Percutaneous Coronary Intervention-Ensuring At-Risk Groups Aren’t Left Behind

    Heart, Lung and Circulation Date published:

  • The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial

    Diabetes & Metabolism Date published:

  • Mechanisms of action of the sodium-glucose cotransporter-2 ( SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial

    Diabetes, Obesity and Metabolism Date published:

  • Optimising mothers’ health behaviour after hypertensive disorders of pregnancy: a qualitative study of a postnatal intervention

    BMC Public Health Date published:

  • Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis

    Diabetes, Obesity and Metabolism Date published:

  • 862-P: Interleukin-6 and Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Post Hoc Analysis of CANVAS Trial

    Diabetes Date published:

  • Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial

    Journal of Diabetes Research Date published:

  • Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials

    Circulation Date published: